Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Can Work Engagement Be a Resource for Reducing Workaholism's Undesirable Outcomes? A Multiple Mediating Model Including Moderated Mediation Analysis.

Scafuri Kovalchuk L, Buono C, Ingusci E, Maiorano F, De Carlo E, Madaro A, Spagnoli P.

Int J Environ Res Public Health. 2019 Apr 18;16(8). pii: E1402. doi: 10.3390/ijerph16081402.

2.

Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report.

De Carlo E, Schiappacassi M, Urbani M, Doliana R, Baldassarre G, Da Ros V, Santarossa S, Chimienti E, Berto E, Fratino L, Bearz A.

Onco Targets Ther. 2018 Dec 10;11:8945-8950. doi: 10.2147/OTT.S184745. eCollection 2018.

3.

Prognostic evaluation in palliative care: final results from a prospective cohort study.

Ermacora P, Mazzer M, Isola M, Pascoletti G, Gregoraci G, Basile D, De Carlo E, Merlo V, Luz O, Cattaruzza M, Orlando A, Bozza C, Pella N, Sacco CS, Puglisi F, Fasola G, Aprile G.

Support Care Cancer. 2019 Jun;27(6):2095-2102. doi: 10.1007/s00520-018-4463-z. Epub 2018 Sep 18.

PMID:
30229339
4.

Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme.

De Carlo E, Gerratana L, De Maglio G, Buoro V, Cortiula F, Gurrieri L, Isola M, Fasola G, Puglisi F, Pizzolitto S, Rizzato S.

J Neurooncol. 2018 Dec;140(3):559-568. doi: 10.1007/s11060-018-2981-7. Epub 2018 Aug 21.

PMID:
30132165
5.

Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study : Complementary and alternative medicine in oncology.

Bozza C, Gerratana L, Basile D, Vitale MG, Bartoletti M, Agostinetto E, Russo S, Follador A, De Carlo E, Pella N, Sottile R, Fasola G, Puglisi F.

J Cancer Res Clin Oncol. 2018 Oct;144(10):2029-2047. doi: 10.1007/s00432-018-2709-2. Epub 2018 Jul 24.

PMID:
30043280
6.

[Checkpoint inhibitors in the decision-making algorithm of advanced non-small-cell lung cancer.]

Fasola G, De Carlo E, Grossi F.

Recenti Prog Med. 2018 Jun;109(6):328-332. doi: 10.1701/2932.29487. Italian.

PMID:
29968861
7.

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience.

De Carlo E, Del Savio MC, Polesel J, Da Ros V, Berto E, Santarossa S, Chimienti E, Fratino L, Bearz A.

Oncotarget. 2018 Feb 26;9(20):15340-15349. doi: 10.18632/oncotarget.24573. eCollection 2018 Mar 16.

8.

MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme.

Gurrieri L, De Carlo E, Gerratana L, De Maglio G, Macerelli M, Pisa FE, Masiero E, Aprile G, Follador A, Puglisi F, Fasola G, Rizzato S, Pizzolitto S.

Future Oncol. 2018 Apr;14(8):699-707. doi: 10.2217/fon-2017-0437. Epub 2018 Mar 9.

PMID:
29521523
9.

INTEGRATED CARE PATHWAYS IN LUNG CANCER: A QUALITY IMPROVEMENT PROJECT.

Fasola G, Menis J, Follador A, De Carlo E, Valent F, Aresu G, De Pellegrin A, Giacomuzzi F, Iuri D, Lugatti E, Parisi G, Pacileo G.

Int J Technol Assess Health Care. 2018 Jan;34(1):3-9. doi: 10.1017/S026646231700441X. Epub 2018 Feb 6.

PMID:
29405098
10.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third-Generation EGFR Tyrosine Kinase Inhibitor.

Bearz A, De Carlo E, Doliana R, Schiappacassi M.

J Thorac Oncol. 2017 Nov;12(11):e181-e182. doi: 10.1016/j.jtho.2017.07.017. No abstract available.

11.

Determinants of Last-line Treatment in Metastatic Breast Cancer.

Cinausero M, Gerratana L, De Carlo E, Iacono D, Bonotto M, Fanotto V, Buoro V, Basile D, Vitale MG, Rihawi K, Fasola G, Puglisi F.

Clin Breast Cancer. 2018 Jun;18(3):205-213. doi: 10.1016/j.clbc.2017.07.008. Epub 2017 Jul 14.

PMID:
28781022
12.

Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?

Aprile G, Negri FV, Giuliani F, De Carlo E, Melisi D, Simionato F, Silvestris N, Brunetti O, Leone F, Marino D, Santini D, Dell'Aquila E, Zeppola T, Puzzoni M, Scartozzi M.

Crit Rev Oncol Hematol. 2017 Jul;115:1-12. doi: 10.1016/j.critrevonc.2017.03.025. Epub 2017 Apr 20. Review.

PMID:
28602164
13.

Immunotherapy for colorectal cancer: where are we heading?

Basile D, Garattini SK, Bonotto M, Ongaro E, Casagrande M, Cattaneo M, Fanotto V, De Carlo E, Loupakis F, Urbano F, Negri FV, Pella N, Russano M, Brunetti O, Scartozzi M, Santini D, Silvestris N, Casadei Gardini A, Puzzoni M, Calvetti L, Cardarelli N, Aprile G.

Expert Opin Biol Ther. 2017 Jun;17(6):709-721. doi: 10.1080/14712598.2017.1315405. Epub 2017 Apr 13. Review. Erratum in: Expert Opin Biol Ther. 2017 Jun;17 (6):791.

PMID:
28375039
14.

Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?

Fontanella C, De Carlo E, Cinausero M, Pelizzari G, Venuti I, Puglisi F.

Cancer Treat Rev. 2016 May;46:80-8. doi: 10.1016/j.ctrv.2016.03.014. Epub 2016 Apr 1. Review.

PMID:
27218867
15.

Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update.

Aprile G, Rihawi K, De Carlo E, Sonis ST.

World J Gastroenterol. 2015 Nov 7;21(41):11793-803. doi: 10.3748/wjg.v21.i41.11793. Review.

16.

Chemotherapy prescribing errors: an observational study on the role of information technology and computerized physician order entry systems.

Aita M, Belvedere O, De Carlo E, Deroma L, De Pauli F, Gurrieri L, Denaro A, Zanier L, Fasola G.

BMC Health Serv Res. 2013 Dec 17;13:522. doi: 10.1186/1472-6963-13-522.

Supplemental Content

Loading ...
Support Center